The Impact of Simvastatin on Lipidomic Markers of Cardiovascular Risk in Human Liver Cells Is Secondary to the Modulation of Intracellular Cholesterol
- Supplementary File 1:
ZIP-Document (ZIP, 573 KiB)
Schooneveldt, Y.L.; Giles, C.; Keating, M.F.; Mellett, N.A.; Jurrjens, A.W.; Paul, S.; Calkin, A.C.; Meikle, P.J. The Impact of Simvastatin on Lipidomic Markers of Cardiovascular Risk in Human Liver Cells Is Secondary to the Modulation of Intracellular Cholesterol. Metabolites 2021, 11, 340. https://doi.org/10.3390/metabo11060340
Schooneveldt YL, Giles C, Keating MF, Mellett NA, Jurrjens AW, Paul S, Calkin AC, Meikle PJ. The Impact of Simvastatin on Lipidomic Markers of Cardiovascular Risk in Human Liver Cells Is Secondary to the Modulation of Intracellular Cholesterol. Metabolites. 2021; 11(6):340. https://doi.org/10.3390/metabo11060340
Chicago/Turabian StyleSchooneveldt, Yvette L., Corey Giles, Michael F. Keating, Natalie A. Mellett, Aaron W. Jurrjens, Sudip Paul, Anna C. Calkin, and Peter J. Meikle. 2021. "The Impact of Simvastatin on Lipidomic Markers of Cardiovascular Risk in Human Liver Cells Is Secondary to the Modulation of Intracellular Cholesterol" Metabolites 11, no. 6: 340. https://doi.org/10.3390/metabo11060340